Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RAPT
- Price
- 0.80
- Stock movement down
- -0.06 (-6.57%)
- Company name
- RAPT Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 28.01M
- Ent value
- 3.06M
- Price/Sales
- 5.30
- Price/Book
- 0.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 4.04%
- 1 year return
- -90.62%
- 3 year return
- -66.85%
- 5 year return
- -45.67%
- 10 year return
- -
Last updated: 2025-04-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RAPT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.30 |
| Price to Book | 0.29 |
| EV to Sales | 0.58 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 34.96M |
| EPS (TTM) | -2.76 |
| FCF per share (TTM) | -2.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.29M |
| Gross profit (TTM) | 4.35M |
| Operating income (TTM) | -114.85M |
| Net income (TTM) | -107.49M |
| EPS (TTM) | -2.76 |
| EPS (1y forward) | -2.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.19% |
| Operating margin (TTM) | -2171.96% |
| Profit margin (TTM) | -2032.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.90M |
| Net receivables | 0.00 |
| Total current assets | 102.60M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 15.27M |
| Total assets | 108.47M |
| Accounts payable | 1.38M |
| Short/Current long term debt | 5.12M |
| Total current liabilities | 10.36M |
| Total liabilities | 12.96M |
| Shareholder's equity | 95.51M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -100.61M |
| Capital expenditures (TTM) | 190.00K |
| Free cash flow (TTM) | -100.80M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -112.55% |
| Return on Assets | -99.10% |
| Return on Invested Capital | -109.65% |
| Cash Return on Invested Capital | -102.83% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.84 |
| Daily high | 0.87 |
| Daily low | 0.80 |
| Daily Volume | 589K |
| All-time high | 48.86 |
| 1y analyst estimate | 2.50 |
| Beta | 0.32 |
| EPS (TTM) | -2.76 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| RAPT | S&P500 | |
| Current price drop from All-time high | -98.36% | -14.24% |
| Highest price drop | -98.36% | -56.47% |
| Date of highest drop | 16 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -59.04% | -11.07% |
| Avg time to new high | 98 days | 12 days |
| Max time to new high | 1314 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
28.01M
Marketcap category
Small-cap
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Employees
70
Website
Investor relations
-
SEC filings
CEO
Brian Russell Wong
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page